Roche Diabetes Care are proud to announce its collaboration with Senseonics Incorporated to launch Eversense XL in the UK. The Eversense XL CGM System is for people who actively manage their diabetes, and provides advanced long term glucose monitoring via an implantable sensor, a removable and rechargeable transmitter, and convenient smartphone app, allowing patients to confidently live their lives with ease.
How does Eversense XL work?
Based on innovative fluorescence technology embedded within a tiny sensor, the Eversense XL CGM system measures glucose in the interstitial fluid (the fluid between cells). A smart transmitter is worn on the arm, directly over the sensor, and wirelessly powers the data transfer from the sensor.
Glucose reversibly binds to the sensor's polymer coating, and the amount of light emitted by the polymer coating rises and falls with changing glucose levels. Photodetectors in the sensor measure the emitted light and wirelessly send these measurements to the transmitter, which then calculates glucose concentration, rate of change and direction. This glucose data is sent wirelessly to the smartphone app that provides real-time tracking, intuitive displays to help identify patterns, and information to help stay in range. The smart transmitter also provides on-body vibration alerts even if your phone is not nearby or is switched off.
With traditional CGM or Flash GM sensors, you must insert a new sensor every 7 – 14 days. With the Eversense XL CGM system, a new sensor is fully inserted under the skin for up to many months.
The Eversense XL CGM system is indicated for people who actively manage their diabetes, and provides advanced glucose monitoring continuously for up to 180 days via an implantable sensor, a removable and rechargeable transmitter, and convenient smartphone app, allowing patients to confidently live their lives with ease.
Eversense XL CGM system frequently asked questions
The multicentre European PRECISE Study (Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor) aimed to determine the accuracy and safety of the Eversense Continuous Glucose Monitoring (CGM) system over successive periods of 30 days for up to 6 months.1
With regard to accuracy, the primary endpoint of MARD (mean absolute relative difference) was 11.6% over the range of 2.2 - 22 mmol/L against venous glucose references (using YSI2300 Stat Plus).
Average reduction in HbA1c over 180 days was 0.35%.
Wear-time compliance for the smart transmitter was good, with a median wear time of 23.5 hours/day (mean 22.3 hours/day). There were no significant adverse events.
Overall participants scored the Eversense CGM system very high on ease of use, convenience, and comfort. Participants were able to wear the transmitter in their everyday setting throughout 180 days of wear. Most stated they would have the Eversense CGM system inserted again.2
- Kropff J et al. Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, 2017; 40: 63 – 68.
- Barnard K et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology. Published October 8, 2017. (https://doi.org/10.1177%2F1932296817735123)